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Abstract
Background: Rheumatoid Arthritis is a progressive and disabling disease, predicted to increase in prevalence over
the next 50 years. Self-management is acknowledged as an integral part in the management of chronic disease.
The rheumatoid arthritis specific self-management program delivered by health professionals was developed by
Arthritis Western Australia in 2006. The purpose of this study was to determine whether this program would achieve
early benefits in health related outcomes, and whether these improvements would be maintained for 12 months.
Methods: Individuals with rheumatoid arthritis were referred from rheumatologists. Participants with co-existing
inflammatory musculoskeletal conditions were excluded. All participants completed a 6-week program. Assessments
occurred at baseline (8 weeks prior to intervention), pre-intervention, post-intervention, and 6 and 12 month
follow ups. Outcomes measured included pain and fatigue (numerical rating scale, 0–10), depression and
anxiety (hospital anxiety and depression questionnaire), health distress, and quality of life (SF-36 version 2).
Results: There were significant improvements in mean [SD] fatigue (5.7 [2.4] to 5.1 [2.6]), depression (6.3 [4.3]
to 5.6 [3.9]) and SF-36 mental health (44.5 [11.1] to 46.5 [9.5]) immediately following intervention, with long
term benefits for depression (6.3 [4.3] to 4.9 [3.9]), and SF-36 subscales mental health (44.5 [11.1] to 47.8 [10.9]), role
emotional (41.5 [13.2] to 46.5 [11.8]), role physical (35.0 [11.0] to 40.2 [12.1]) and physical function (34.8 [11.5]
to 38.6 [10.7]).
Conclusion: Participants in the program recorded significant improvements in depression and mental health
post-intervention, which were maintained to 12 months follow up.
Background
Arthritis is one of the most prevalent chronic diseases
in Australia [1], with nearly 0.5 million affected by
the most severe type, rheumatoid arthritis (RA) [2].
Rheumatoid arthritis is an autoimmune disease of un-
known aetiology [3, 4]. More women are affected by
RA than men with 2.6 % and 1.6 % of the Australian
population respectively affected [5]. By 2050, it is pro-
jected to affect 0.9 million Australians [1].
Rheumatoid arthritis causes progressive deterioration,
with subsequent functional decline [6], leading to disability,
participation restrictions and impaired quality of life
[7]. Individuals with RA experience greater psycho-
logical distress than the general population [8]. Further-
more, over 80 % of individuals with RA have clinically
important fatigue [9]. Pain, a cardinal symptom of RA,
affects up to 84 % of individuals [10], and negatively
impacts on multiple aspects of life [11].
Self-management (SM) is increasingly being accepted
as an integral part in the management of chronic dis-
ease [12]. Self-management interventions (SMIs) are
patient-centred, problem focused and action-oriented
[13, 14], addressing physical and psychosocial issues
[15]. They utilise educational, behavioural and cognitive
strategies [12, 14] to enhance patient participation in
treatment [16].
Education programs (EPs) teaching SM skills are be-
lieved to be more effective than information-only EPs in
* Correspondence: jeanm@arthritiswa.org.au
3Arthritis and Osteoporosis Western Australia, Perth, Western Australia,
Australia
5Health, Education & Research Program Manager, Arthritis and Osteoporosis
Western Australia, PO Box 34, Wembley WA 6913, 17 Lemnos St, Shenton Park,
Western Australia 6008, Australia
Full list of author information is available at the end of the article
© 2015 Vermaak et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Vermaak et al. BMC Musculoskeletal Disorders  (2015) 16:214 
DOI 10.1186/s12891-015-0663-6
improving clinical outcomes in RA patients [17, 18].
However, reported benefits are equivocal and the bene-
fits are temporary [17]. Systematic reviews have reported
a trend towards small benefits from arthritis SM pro-
grams [16, 19–21]. Overall, SMIs improve knowledge,
SM skills, self-efficacy (SE), and some aspects of health
status [22, 23]. There is evidence supporting positive
outcomes for disease-specific SMIs [16, 19, 20], includ-
ing osteoarthritis [24]. Numerous studies have evaluated
EPs and generic SMIs, however, only a small number
have examined disease-specific SMIs. Disease-specific
SMI are reported to produce better outcomes com-
pared to generalised non-specific chronic disease
SMIs [25, 26], and it is thought that this approach
may be more beneficial for people with RA. The available
evidence suggests that provision of tailor-made programs
may be more beneficial for chronic disease management
[27, 28] and thus identification of individual educational
needs becomes imperative [29].
The RA SMI was developed by Arthritis Western
Australia in 2006, using a participatory action research
model, utilising the Plan, Do, Study, Act approach. The
program was based on the findings of an educational
needs assessment tool survey completed by a total of
157 RA patients from United Kingdom (n = 125) and
Western Australia (n = 32) in 2005 [30]. Findings dem-
onstrated that people with RA have specific needs [30].
It was on this basis, that the RA SMI was developed.
Participant needs catered for incorporated offering the
program in a community setting with flexible delivery
times including evenings and weekends as well as the
content of the program. The intervention program is
person-centred and based on SM principles, including
cognitive behavioural therapy and SE constructs.
Purpose of study
The aim of this study was to determine whether the RA
SMI would achieve immediate improvements in health
related outcomes following program involvement, and
whether these improvements would be maintained for
12 months after course completion.
Methods
Study design
A one group (within subjects) repeated measures study
was used to determine change over time.
This study was approved by the Human Research Ethics
Committee at Curtin University, Western Australia
(PT0021, 2005). All participants provided written informed
consent.
Participants
Patients with RA were recruited by referral from spe-
cialist rheumatologists in Western Australian public
hospitals and private sectors. Inclusion criteria were
clinical diagnosis of RA made by their treating rheuma-
tologist, aged ≥18 years, and the ability to speak and
understand English. Participants with co-existing inflam-
matory musculoskeletal conditions were excluded. Diag-
nostic criteria were not specified but at the discretion of
the clinical rheumatologist treating the patient.
Outcome measures
Outcome measures evaluated pain, fatigue, depression,
anxiety, SE, health distress and health related quality of
life. Participants completed a set of baseline (BL) ques-
tionnaires 8 weeks prior to the commencement of the
program , then again one week prior to the first SM ses-
sion (pre-intervention), one week after the 6 week pro-
gram (post-intervention), with follow up periods at 6
and 12 months.
Pain and Fatigue were each measured via a ten-point
incremental numerical rating scale. Numerical rating
scales have adequate discriminative power for describing
pain intensity [31], have good sensitivity [32] and the re-
liability is excellent (r = 0.94) [33].
Depression and Anxiety were measured using the
14-item Hospital Anxiety and Depression scale, con-
sisting of 7 anxiety and 7 depression items, scored
separately [34] which is reliable (Cronbach’s alpha
0.68 to 0.93) and valid [34, 35].
Self-Efficacy was measured using an 8-item question-
naire developed by Stanford University from the original
20-item arthritis SE scale [36]. The scale reflects how par-
ticipants rate their certainty in performing tasks along a
continuum. This scale is reliable and valid [36, 37] (http://
patienteducation.stanford.edu/research/searthritis.html).
Health Distress was measured using a 4 item question-
naire to assess the level of fear, worry and/or frustration
each individual felt in relation to their disease [37]. Scores
range from 0 to 5 with higher scores indicating more dis-
tress about health (http://patienteducation.stanford.edu/
research/searthritis.html).
Quality of life was measured using the Short-Form 36
Version 2 questionnaire (SF-36). The SF-36 consists of 36
questions and includes 8 component subscales reflecting
physical and mental status [38], including physical func-
tion, role physical, bodily pain, general health, vitality, so-
cial function, role emotional and mental health. The SF-36
is a well-established outcome assessment in RA [39, 40]
and is reliable and valid [41–43].
Intervention
The newly developed RA SMI program was offered to pa-
tients managed in a Rheumatology Outpatient Department
of a tertiary hospital and in a community setting. Groups of
8–15 participants attended 1 session each week for 6 con-
secutive weeks, with each 2.5 h in duration. Attendance
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and assessment time-points were recorded. Modules are
inter-related and cumulative building on previously learned
information. The program was delivered by the same two
health professionals. Uniformity of the RA program across
and within groups was maintained by using scripted facili-
tator’s manual.
The program content concentrated on disease-specific
education including:
 Psychological impact and management strategies










Personal development focused on individual weekly
goal setting, problem solving, relaxation techniques, and
cognitive behavioural therapy to assist in long term be-
havioural changes. Participants were encouraged to in-
corporate techniques learnt at each session into their
activities of daily living, returning to discuss their experi-
ence next week.
Data analysis
Data was analysed using SPSS version 19. One way
(repeated measures) analysis of variance (ANOVA)
with time (baseline, pre-intervention, post-intervention, 6
and 12 months follow up) as the independent variable was
utilised. Mauchly’s Test of Sphericity was performed on all
data. When the Mauchly’s statistic was significant, with
the sphericity assumption violated for the univariate ap-
proach to repeated-measures ANOVA, this was corrected
with the Greenhouse-Geisser adjustment. Where tests
of within-subjects comparisons were significant, im-
plying a significant change over time, post-hoc linear
contrasts were performed to compare each time point
to the pre-intervention time point. Significant im-
provements between BL and pre-intervention were
interpreted to indicate spontaneous improvement,
suggesting that changes following the intervention
may also be spontaneous. Statistical significance was
inferred at p < 0.05.
Results
A total of 113 participants (96 [85 %] female) with a
mean (SD) age of 54 (13) were enrolled in the study.
Ninety-six participants completed data collection at all
time-points. Of these participants 92 (96 %) attended
80 % or more of the intervention sessions.
All patients in the study were referred by and being
treated by a clinical Rheumatologist at either a public
hospital or private clinic. Treatment prescribed by these
specialist physicians was at their discretion in consult-
ation with the patient taking into account efficacy, toler-
ance, toxicity, cost, compliance and patient preference.
At baseline, 43 %, 76 % and 13 % of participants were
taking steroids, disease modifying anti-rheumatic drugs
(DMARDs) and biologics (bDMARDs), respectively.
Steroid use decreased to 35 % post-intervention and
32 % at 12 months. DMARDs use increased to 79 % at
pre-intervention but stabilised at 76 % post-intervention
and at 12 months. The use of bDMARDs continually in-
creased from 15 % pre-intervention to 16 % post-
intervention and 24 % at 12 months. At 12 months,
59 % of participants were taking symptomatic treatments
such as paracetamol and NSAIDS.
Fatigue and pain
Fatigue and pain remained stable during the pre-
intervention control period. The fatigue numerical
rating score decreased significantly from a mean (SD)
of 5.7 (2.4) pre-intervention to 5.1 (2.6) post-intervention,
however, there was a small rebound to 5.2 (2.7) at 6 and
12 months which was no longer statistically significant
(Table 1). Pain numerical rating score showed a small non-
significant decrease throughout the course of the study.
Anxiety and depression
Levels of anxiety and depression remained stable during
the control period. Anxiety had a non-significant reduc-
tion from a mean (SD) of 7.4 (3.9) to 6.9 (3.9) during the
6 week intervention. At 6 months, anxiety had decreased
to 6.7 (4.0) and this level was maintained at 6.7 (4.5) at
12 months. Depression improved significantly post-
intervention and was maintained to 12 months (Table 1).
Health distress
Health distress lessened significantly during the pre-
intervention control period. Post-intervention, only a
small non-significant reduction was observed from
mean (SD) 2.1 (1.1) to 2.0 (1.0). Further significant im-
provements in health distress were observed at 6 and
12 month (Table 1).
Self-efficacy
During the pre-intervention period, a significant im-
provement in SE was observed, with no incremental sig-
nificant changes post-intervention.
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Quality of life
The SF-36 subscales of mental health, role emotional,
general health and physical function remained un-
changed during the pre-intervention control period,
while social function, vitality, bodily pain and role phys-
ical demonstrated significant improvements. Only mental
health showed a significant improvement immediately
post-intervention and mental health remained signifi-
cantly better than pre-intervention at both 6 and
12 months. Although there were only small non-significant
improvements in role emotional and physical function at
post-intervention, improvements continued over time and
were statistically significant by 6 and 12 months (Table 1).
Discussion
This, one of the first studies of SM specifically for
people with RA delivered by health professionals, dem-
onstrated significant improvements in some, but not all,
aspects of health and well-being measured. This results
appears superior to those from non-disease specific SM
programs, however, participants with RA included in
generic SM arthritis studies are usually in the minority
[23, 25, 44, 45], consequently presenting limitations to
interpreting their results for this subset of participants.
It is not clearly understood how SMIs affect change in
health outcomes. Several factors that may have an affect
are motivation to participate and to change health be-
haviour, deteriorating health, stressful life events [28],
the concept of readiness to change [46, 47], and lower
quality of life [40]. Our results highlight that some
changes may only develop in the long term. For example
improvements in anxiety, role emotional and physical
function were only evident at 6 months.
Improvements in anxiety, depression and mental
health are important due to their severe impact. Par-
ticipants were taught how to manage the psycho-
logical impacts of RA through relaxation and distraction
techniques. Improving these SM skills should enable bet-
ter coping with the challenges imposed by RA [48–50].
Better knowledge and understanding of disease em-
powers and enhances a sense of control, and conse-
quently people feel less anxious [7]. Armed with
better behavioural and cognitive strategies to manage
their disease, they are likely to be more confident,
and feel less uncertain about the consequences of
their disease, [48, 51], with associated improvements
in mental health and depression [49, 52, 53]. Our re-
sults reflect this as participants reported experiencing
fewer role limitations due to emotional problems.
Barlow et al. [44] found similar improvement in anx-
iety and depression following participation in the
Arthritis Self-Management Program (ASMP). How-
ever, no immediate post-intervention results were re-
corded, and results were for the combined arthritis
population, therefore making it difficult to distinguish
effects within the RA participants.
There was a significant improvement in health distress
during the pre-intervention control period, therefore
Table 1 Results for outcomes: fatigue, pain, anxiety, depression, health distress, self-efficacy, and SF-36 at baseline, pre-intervention,
post-intervention, 6- and 12-months follow up. Data are mean (SD)
Outcomes Baseline Pre-Ix Post-Ix 6 Months 12 Months
Fatigue (0–10) 6.1 (2.4) 5.7 (2.4) 5.1 (2.6)a 5.2 (2.7) 5.2 (2.9)
Pain (0–10) 5.1 (2.4) 4.9 (2.2) 4.8 (2.7) 4.9 (2.7) 4.4 (2.9)
Anxiety (0–21) 7.8 (4.1) 7.4 (3.9) 6.9 (3.9) 6.7 (4.0)a 6.7 (4.5)
Depression (0–21) 6.1 (3.8) 6.3 (4.3) 5.6 (3.9)a 5.2 (3.8)a 4.9 (3.9)a
Health distress (0–5) 2.3 (1.1)a 2.1 (1.1) 2.0 (1.0) 1.7 (1.2)a 1.4 (1.1)a
Self-efficacy (0–10) 5.5 (2.1)a 5.9 (1.9) 6.1 (2.1) 6.1 (2.3) 5.9 (2.8)
SF-36 (0–100)
Mental health 44.1 (10.6) 44.5 (11.1) 46.5 (9.5)a 47.2 (10.6)a 47.8 (10.9)a
Role emotional 40.5 (13.4) 41.5 (13.2) 42.6 (13.4) 45.3 (13.1)a 46.5 (11.8)a
Social function 39.6 (12.3)a 41.5 (12.1) 42.1 (11.1) 42.8 (13.1) 43.3 (11.9)
Vitality 38.8 (10.3)a 40.9 (10.9) 41.7 (10.4) 43.7 (11.5)a 43.7 (12.2)a
General health 39.3 (10.9) 40.2 (11.5) 39.3 (11.3) 41.0 (11.6) 41.5 (11.5)
Bodily pain 37.3 (7.2)a 38.9 (7.6) 38.8 (7.5) 39.8 (9.0) 40.6 (9.4)
Role physical 32.7 (10.2)a 35.0 (11.0) 36.2 (12.1) 39.3 (13.0)a 40.2 (12.1)a
Physical function 34.6 (11.0) 34.8 (11.5) 35.6 (11.3) 37.3 (11.4)a 38.6 (10.7)a
asignificantly different to pre-intervention (p < 0.05). Repeated measures ANOVA
Decreasing scores in fatigue, pain, anxiety, depression and health distress signify improvement, while increasing scores in self-efficacy and SF-36
signify improvement
Ix Intervention
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results need to be interpreted with caution. The im-
provement during the control period could be attributed
to the participants’ knowledge that they were joining the
SMI in the near future and looking forward to a sup-
portive environment with qualified health professionals
providing reassurance. However, as for anxiety, depres-
sion and mental health, it is plausible that a greater
knowledge and understanding of disease gained during
the SMI, in addition to SM strategies, could reduce fear,
worry and/or frustration felt in relation to RA. Other
studies evaluating the effect of ASMP in an arthritis
population support our findings [23, 25, 45]. Interest-
ingly, when Lorig et al. [23] evaluated the effect on the
RA population alone, no significant effect was found.
Evidence from our study suggests participation in a
disease-specific SMI reduces the distress associated with
RA for up to 1 year.
During the program, participants were provided with
relaxation and energy conservation and pacing strategies
to assist with managing fatigue. It is plausible that this
SMI assisted participants to establish a balance between
rest and exercise resulting in overall improvements in fa-
tigue. In addition, participants also learned to recognise
fear-avoidant behaviour, which can affect physical func-
tioning. Instead they were able to implement alternative
approaches to manage activities. Fatigue is influenced by
perceptions of RA and sense of control over the conse-
quences [54]. Therefore, altering people’s perceptions
may subsequently mediate improvement in fatigue [49].
Other studies have reported conflicting results for im-
provement in fatigue. Following participation in the
ASMP the reported improvement was maintained for
1 year [23, 25, 46]. However, this was not true for the
RA population alone [23].
This intervention was designed to enhance patients’
abilities to control their pain, and to utilise adaptive pain
management strategies. However no significant reduc-
tion in pain was recorded. This finding is not unex-
pected. Effective pain management can be difficult to
achieve in patients with RA as it relates to inflammation
rather than mechanical factors. Strategies to supress in-
flammation, especially pharmacological, would be the
most effective. Our findings are consistent with previous
studies that report that many patients with RA believe
their pain is uncontrollable [14], and isolated SMI may
not have been sufficiently potent to change this. More-
over, pain often persisted regardless of concurrent treat-
ment and co-management with their usual clinician
based care [7, 10]. Integration of a SM program into
usual clinician based care as opposed to parallel delivery
has been shown to have a positive impact on adherence
to medical therapy and disease activity scores [55]. As
we did not measure either of these outcomes in our
study we cannot comment definitively on whether lack
of improvement in disease activity may have been associ-
ated with the limited improvements in pain and fatigue
observed in our study.
Changes in SE regarding pain and other symptoms re-
late to changes in perceived health status [56]. In people
with RA there is a gradual deterioration in physical func-
tion [6, 57] as perpetuated by disease progression leading
to disability, and impaired quality of life [58]. Patients with
RA often consider their health as deteriorating, and this
may be the reason for the report of no improvements in
general health in the study.
Self-management interventions are often associated
with improvements in SE. This is true for our study,
however the improvement was not statistically signifi-
cant [23, 25, 46]. Although the study used feedback
questionnaires in the program to further optimise SE,
there are other factors that could have affected the re-
sults [59]. Firstly the age and disease duration of the
hospital cohort may have an influence as they had long
disease duration and severe deformities [60]. Also the
participants may have set unachievable goals and unreal-
istic expectations, and the subsequent failure weakened
SE [14, 61]. The small but insignificant improvement in
SE is consistent with findings following an online ASMP
[23]. This study’s findings are also consistent with the
previously reported negative association between pain
ratings and perceived SE [60].
As this was a SMI study, medical interventions were
not part of the assessment brief. This was managed in
parallel by independent clinicians without specific know-
ledge of the SMI interventions and based on their inde-
pendent individual patient assessments. Ongoing medical
management is an important confounding variable that
we were unable to control for in this study. Given the pro-
gressive destructive nature of the disease, we did not con-
sider it ethical to withhold medical revision during the
12 month study period. Changes in medication have the
potential to influence a number of the variables measured.
This may in part explain the findings of significantly im-
proved health distress, SE, bodily pain and role physical
during the control period. It is plausible that better con-
trolled pain improves SE, minimising perceived role limi-
tations due to physical functioning, and reduced health
distress. Use of DMARDS did not change overall, however
bDMARDS did and may have a significant impact on out-
come measures. Biologics are considered the ‘ideal’ and
the most effective treatment in combination with a
DMARD in terms of disease control and or remission.
Therefore the increase in prescription rates may be con-
sidered a strength of this program as it encouraged more
optimal treatment. This may be a consequence of better
education and empowerment of participants. Improving
education and self-efficacy in conjunction with optimisa-
tion of medical management to reduce symptoms of
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inflammation and signs of destruction would be desirable
to optimise patient outcomes.
One limitation of the study is the design. A single
group repeated measures design was used to evaluate
short and long term benefits, so all participants could
partake in the intervention. The effect of time and “any
contact” with any care provider is difficult to factor in or
correct for. Nevertheless, longitudinal and observational
studies provide essential information about the course
and outcome of rheumatic diseases that cannot be pro-
vided by randomised controlled trials [62]. However, to
further develop and examine the effectiveness of the RA
SMI a large randomised controlled trial would be required.
Findings from this study are important for implement-
ing future RA SMIs. These interventions are relatively
inexpensive and safe forms of treatment. They also sup-
port current health care funder priorities of shifting the
management of chronic diseases into the primary care
environment and the emphasis on person centred man-
agement with less reliance on specialist centres.
Conclusions
In conclusion implementing a RA SMI demonstrated
significant benefits. Any contact with a supportive health
care provider with a specific disease focus, appears to be
beneficial for patients with RA. There appears to be add-
itional benefit of adding health professional intervention
and SMI. Improvements in depression and mental health
were observed in response to the SMI. Moreover, they
were maintained at 12 months. The reported increase in
prescription of bDMARDS by patients’ medical practi-
tioner should be viewed as a positive and essential ad-
junctive strategy for disease modification and reducing
impairment and disability. Empowering patients through
education may allow them to be more proactive in seek-
ing better evidence based medical treatments earlier. As
this was one of the first studies on RA SMI future devel-
opment and evaluation via a randomised controlled trial
is necessary to continue to optimise the positive out-
comes of the program. In particular refinement of the
program focussing on the SE and pain outcomes needs
to be planned, implemented and evaluated.
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